Mouse Monoclonal CBLL2 Antibody

The CBLL2 antibody targets the Cbl proto-oncogene-like 2 (CBLL2), also known as Hakai, a RING finger-type E3 ubiquitin ligase first identified in 2002. CBLL2 plays a key role in regulating E-cadherin ubiquitination and degradation, a process critical for epithelial-mesenchymal transition (EMT) during embryogenesis and cancer metastasis. It interacts with tyrosine-phosphorylated E-cadherin, promoting its internalization and lysosomal degradation, thereby weakening cell-cell adhesion. Beyond EMT, CBLL2 is implicated in DNA damage response, cell signaling, and RNA metabolism. Dysregulation of CBLL2 has been linked to tumor progression, particularly in colorectal, breast, and lung cancers, where its overexpression correlates with poor prognosis. Antibodies against CBLL2 are widely used in research to study its expression patterns, subcellular localization, and functional interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. Recent studies also explore its potential role in neurological disorders and viral infections. Commercial CBLL2 antibodies are typically raised against specific epitopes in its N-terminal or C-terminal regions, with validation in knockout controls being essential due to cross-reactivity concerns with related proteins like Cbl.